The Meaning of Adherence When Behavioral Risk Patterns Vary: Obscured Use- and Method-Effectiveness in HIV-Prevention Trials

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  de Bruin, Marijn ^a   Viechtbauer, Wolfgang ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONDOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; PATIENT COMPLIANCE; PREVALENCE; PROBABILITY; RISK ASSESSMENT; SEXUAL BEHAVIOR; STATISTICAL MODEL;

ALGORITHMS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; PROBABILITY; RISK; RISK-TAKING; SELF ADMINISTRATION; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84865644958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044029     Document Type: Article

References (39)

1. UNAIDS (2010) Global report: UNAIDS report on the global epidemic. New York: United Nations: UNAIDS.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England journal of medicine 363: 2587-2599.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
4. Network MT MTN statement on decission to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in Women.
5. Network MT MTN statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women.
6. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr, (2008) Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 372: 585-599.
7. Padian NS, McCoy SI, Balkus JE, Wasserheit JN, (2010) Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 24: 621-635.
8. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ, (2008) Persisting with prevention: the importance of adherence for HIV prevention. Emerging themes in epidemiology 5: 8.
9. Urquhart J (1996) Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. European heart journal 17 Suppl A: 8-15.
10. Vrijens B, Goetghebeur E, (1997) Comparing compliance patterns between randomized treatments. Controlled clinical trials 18: 187-203.
11. Blaschke TF, Osterberg L, Vrijens B, Urquhart J, (2012) Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 52: 275-301.
12. Harter J, Peck C, (1991) Chronobiology: suggestions for integrating it into drug development. Annals New York Academy of Sciences 618: 563-571.
13. Lagakos S, Gable A (2008) Methodological Challenges in Biomedical HIV Prevention Trials. Washington DC: The National Academies Press.
14. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, et al. (2010) A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PloS one 5: e11600.
15. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, et al. (2010) Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PloS one 5: e11632.
16. Turner AN, De Kock AE, Meehan-Ritter A, Blanchard K, Sebola MH, et al. (2009) Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. Journal of clinical epidemiology 62: 759-765.
17. Mattson CL, Campbell RT, Karabatsos G, Agot K, Ndinya-Achola JO, et al. (2010) Scaling sexual behavior or "sexual risk propensity" among men at risk for HIV in Kisumu, Kenya. AIDS and behavior 14: 162-172.
18. Boily MC, Baggaley RF, Wang L, Masse B, White RG, et al. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9: 118-129.
19. Weller S, Davis K (2002) Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev: CD003255.
20. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS medicine 2: e298.
21. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643-656.
22. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73-83.
23. Pinkerton S, Abramson P (1998) The Bernoulli-Process Model of HIV Transmission: Applications and Implications. In: Holtgrave D, editor. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum Press. 13-32.
24. Holtgrave D, Leviton L, Wagstaff D, Pinkerton S, (1997) Cumulative Probability of HIV Infection: A Summary Risk Measure for HIV Prevention Intervention Studies. AIDS and Behavior 1: 169-172.
25. Foss AM, Vickerman PT, Heise L, Watts CH, (2003) Shifts in condom use following microbicide introduction: should we be concerned? AIDS 17: 1227-1237.
26. Rottingen JA, Garnett GP, (2002) The epidemiological and control implications of HIV transmission probabilities within partnerships. Sex Transm Dis 29: 818-827.
27. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, et al. (2009) South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers? Cape Town: HSRC Press.
28. Welz T, Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K, et al. (2007) Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS 21: 1467-1472.
29. Powers KA, Poole C, Pettifor AE, Cohen MS, (2008) Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 8: 553-563.
30. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, et al. (2008) Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PloS one 3: e3784.
31. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, et al. (2007) SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PloS one 2: e1312.
32. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. The New England journal of medicine 359: 463-472.
33. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
34. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine 365: 493-505.
35. Vickerman P, Foss A, Watts C, (2008) Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials. J Acquir Immune Defic Syndr 48: 460-467.
36. Pinkerton SD, Galletly CL, McAuliffe TL, DiFranceisco W, Raymond HF, et al. (2010) Aggregate versus individual-level sexual behavior assessment: how much detail is needed to accurately estimate HIV/STI risk? Evaluation review 34: 19-34.
37. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, et al. (2010) A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PloS one 5: e11094.
38. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M, et al. (2011) Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. International journal of epidemiology 40: 922-930.
39. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR, (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.